| | ||||||||||
| 1 | INN | Class | Route (list) | PK parameters= Cmax; Tmax; F: bioavailability; t1/2: half-life; VD: volume of distribution; Cl: clearance; PPB: plasma protein binding;(EQN means that value was calculated using VD=(Cl*t1/2)/0.693) | Primary Target and PDB code of Protein-Drug complex | Targets from DrugCentral | Links | |||
| TOVORAFENIB
| TOVORAFENIB | ANTINEOPLASTIC | ORAL | Cmax 13.6 MICROMOLAR Tmax 3 HOUR VD 103.8 LITER PPB 97.5 PERCENT Cl 1.2 LITER / HOUR HT 56 HOUR SOLUBILITY LOWER THAN 3 MICROGRAMS PER MILLILITER FROM PH 1.2 TO 8 | TYPE II RAF KINASE (MUTANT BRAF V600E, WILD-TYPE BRAF, AND WILD-TYPE CRAF) PDB 8F7O (BRAF KINASE IN COMPLEX WITH TAK580 (TOVORAFENIB)) LIGAND CODE = QOP (link to the list of PDB complexes) Download experimental 3D coordinates of QOP with added hydrogens | - more at DrugCentral | EMA | |||
